ストックスクリーナーアプリを入手
0.7816
1.23%
-0.0097
アフターアワーズ：
.78
-0.0016
-0.20%
Rein Therapeutics Inc (RNTX) 最新ニュース
Rein Therapeutics Inc (RNTX) Cash Flow - TradingKey
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey
Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView
Rein Therapeutics (RNTX) Proxy filing Summary - Quartr
Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks
Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com South Africa
Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com
Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com
Rein Therapeutics expects initial lung-trial data in 2H 2026 - Stock Titan
Rein Therapeutics Price Target Announced at $4.00/Share by Maxim Group - Moomoo
Rein Therapeutics (RNTX) Gains Buy Rating and $4 Price Target fr - GuruFocus
RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus
Rein Therapeutics (RNTX) AGM 2026 Summary - Quartr
Transcript : Rein Therapeutics Inc.Shareholder/Analyst Call - marketscreener.com
RNTX: All agenda items, including director elections and share authorization, were approved - TradingView
RNTX: All agenda items, including director elections and share increase, were approved - TradingView
Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support LevelMcClellan Summation - DonanımHaber
Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to EBITDA forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Enterprise value to revenue forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Price to sales forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView
Enterprise value to EBIT forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves - dars.gov.et
RNTXRein Therapeutics Inc Latest SEC Filings - Finviz
Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rein Therapeutics Inc.(NasdaqCM: RNTX) added to Russell 3000E Value Benchmark - marketscreener.com
Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX) - TradingView
RNTX Forecast — Price Target — Prediction for 2027 - TradingView
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrower‑than‑expected loss as clinical pipeline advances - dars.gov.et
Rein Therapeutics Inc (RNTX) Institutional Confidence - TradingKey
Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97Sweep Order Flow - DonanımHaber
RNTX Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionFinal Results - dars.gov.et
Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria
Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com
Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
RNTX Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline as Pre-Revenue Biotech Advances PipelineInterim Report - newsline.com
Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Better-than-Expected Loss Highlights Cost DisciplineEarnings Miss Streak - dars.gov.et
Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay - Stock Titan
RNTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Rein Therapeutics (RNTX) Holds Steady at $1.11, Testing Key SupportLow Vol Factor - dars.gov.et
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):